Gilbert Chu
Targeting operable mutations in cancer driver genes has helped precision oncology make major strides. Recent research has started to look into the potential of tumor transcriptome to direct patient treatment in an effort to increase treatment options. Here, we offer SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a framework for precision oncology that uses genetic interactions to forecast patient response to cancer therapy from the transcriptome of the tumour. 35 published targeted and immunotherapy clinical trials from 10 distinct cancer types are used as a large sample for the testing of SELECT. In 80% of these clinical trials and the most recent multi-arm WINTHER experiment, it accurately predicts the patients' responses. The code and predicted signatures are made available for academic usage in the public, providing a foundation for potential future clinical research.